| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Vireo Growth Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.35 |
| 52 Week High | CA$0.63 |
| 52 Week Low | CA$0.15 |
| Beta | 1.34 |
| 11 Month Change | -6.91% |
| 3 Month Change | -8.62% |
| 1 Year Change | 98.86% |
| 33 Year Change | -74.07% |
| 5 Year Change | -70.09% |
| Change since IPO | -92.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0ZF | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -8.4% | -1.8% | -1.8% |
| 1Y | 98.9% | -12.8% | 13.6% |
Return vs Industry: 0ZF exceeded the German Pharmaceuticals industry which returned -12.8% over the past year.
Return vs Market: 0ZF exceeded the German Market which returned 13.6% over the past year.
Price Volatility
| 0ZF volatility | |
|---|---|
| 0ZF Average Weekly Movement | 21.0% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0ZF's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0ZF's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 438 | Amber Shimpa | vireohealth.com |
Vireo Growth Inc. operates as a cannabis company in the United States. The company cultivates, manufactures, processes, and distributes medical and adult-use cannabis products. It sells cannabis products through its network of Green Goods and other Goodness Growth branded retail dispensaries and third-party dispensaries in Maryland, Minnesota, and New York.
Vireo Growth Inc. Fundamentals Summary
| 0ZF fundamental statistics | |
|---|---|
| Market cap | €94.16m |
| Earnings (TTM) | -€15.75m |
| Revenue (TTM) | €89.85m |
1.0x
P/S Ratio-6.0x
P/E RatioIs 0ZF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0ZF income statement (TTM) | |
|---|---|
| Revenue | US$98.04m |
| Cost of Revenue | US$47.00m |
| Gross Profit | US$51.05m |
| Other Expenses | US$68.24m |
| Earnings | -US$17.19m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 13, 2024
| Earnings per share (EPS) | -0.075 |
| Gross Margin | 52.07% |
| Net Profit Margin | -17.53% |
| Debt/Equity Ratio | -320.5% |
How did 0ZF perform over the long term?
See historical performance and comparison